Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 12/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041645 | 0.83 | C5AR1 (0.46) | C5AR1 | |
| SCHEMBL13041624 | 0.77 | C5AR1 (0.47) | C5AR1ALDH1A1 | |
| SCHEMBL13041636 | 0.72 | C5AR1 (0.45) | C5AR1KMT2ANPC1ALDH1A1TSHR | |
| SCHEMBL2866213 | 0.67 | MAPK1 (0.52) | MAPK1AADATGRM4 | |
| SCHEMBL13041632 | 0.65 | IDH1 (0.37) | MAPK1C5AR1ALDH1A1IDH1 | |
| SCHEMBL13041627 | 0.65 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL27266585 | 0.63 | SCN9A (0.47) | MAPK1AADATSCN9A | |
| SCHEMBL13041626 | 0.62 | OPRM1 (0.39) | C5AR1ALDH1A1 | |
| SCHEMBL21257797 | 0.62 | MEN1 (0.43) | MAPK1KMT2AAADATMEN1 | |
| SCHEMBL1477268 | 0.61 | MAPK1 (0.71) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | MAPK1 2919/4885C5AR1 265/4885KMT2A 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.